



## Cytokinetics to Host Investor Event Following Presentation of Results from ATOMIC-AHF at the European Society of Cardiology Congress 2013

August 14, 2013 8:00 PM EDT

**South San Francisco, CA, August 14, 2013** - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today its plans to host an Investor Event following the presentation of the results from the ATOMIC-AHF trial at the European Society of Cardiology Congress 2013. The Cytokinetics event will be held on Tuesday, September 3<sup>rd</sup> from 2:00 PM - 3:00 PM Central European Time. The event will be held in the Algiers Room, Village 4 at the RAI Convention Center in Amsterdam, Netherlands.

Cytokinetics will be represented by Robert Blum, President and Chief Executive Officer; Dr. Fady I. Malik, Senior Vice President, Research and Early Development; and Dr. Andrew A. Wolff, Senior Vice President of Clinical Research and Development and Chief Medical Officer. Also participating will be Dr. John R. Teerlink, Director of the Heart Failure Program and of the Clinical Echocardiography Laboratory at the San Francisco Veterans Affairs Medical Center, California, and Dr. John J.V. McMurray, Professor of Medical Cardiology at the University of Glasgow, Scotland, United Kingdom.

Presentations and accompanying slides will be simultaneously webcast beginning at 2:00 PM Central European Time (8:00 a.m. Eastern Time) and can be accessed through the Investor Relations section of the Cytokinetics' website at [www.cytokinetics.com](http://www.cytokinetics.com). The live audio of the forum will also be accessible via telephone to investors, members of the news media and the general public by dialing either (866) 999-CYTK (2985) (United States and Canada) or (706) 679-3078 (International) and typing in the passcode 31517709.

An archived replay of the webcast will be available on the Presentations page in the Investor Relations section of Cytokinetics' website until September 10, 2013. The replay will also be available via telephone from September 3, 2013 at 2:00 p.m. Eastern Time until September 10, 2013 by dialing (855) 859-2056 (United States and Canada) or (404) 537-3406 (International) and typing in the passcode 31517709.

### About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, *omecamtiv mecarbil*, is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide to develop and commercialize *omecamtiv mecarbil* and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing *tirasemtiv*, a fast skeletal muscle activator, as a potential treatment for diseases and medical conditions associated with neuromuscular dysfunction. *Tirasemtiv* is currently the subject of a Phase II clinical trials program and has been granted orphan drug designation and fast track status by the U.S. Food and Drug Administration and orphan medicinal product designation by the European Medicines Agency for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment. Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107, a skeletal muscle activator structurally distinct from *tirasemtiv*, for non-neuromuscular indications. All of these drug candidates have arisen from Cytokinetics' muscle biology focused research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at [www.cytokinetics.com](http://www.cytokinetics.com).

*This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics' drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.*

### Contact:

Cytokinetics, Inc.  
Joanna L. Goldstein (Investors & Media)  
(650) 624-3000